• Mashup Score: 4

    Author links open overlay panel Alison May Berner MBBS, MSc, PhD, MRCP ⁎ † ‑ Royal College of Radiologists. Improving cancer care for sexual and gender minorities. Available at:… LGBT Foundation. If we’ re not counted we don’ t count – Good practice guide to monitoring sexual orientation and trans… There are more references available in the full text version of this

    Tweet Tweets with this article
    • Pleased to share this article on how we improve #cancer care for the #transgender community: https://t.co/SN6IZM7swj πŸ³οΈβ€βš§οΈ Thanks to @IJROBP for inviting me to speak out on this and to @LishSmartMD and colleagues for their excellent linked article: https://t.co/2PqGZUaNHV

  • Mashup Score: 15

    Health Secretary promises consultation on NHS constitution, calling for a “common-sense” approach.

    Tweet Tweets with this article
    • To all my patients, colleagues and friends who this would affect, I promise I will fight any such policy change with every fibre of my being. Very sad and angry that this is on the government agenda πŸ˜” #TransRightsAreHumanRights πŸ³οΈβ€βš§οΈ https://t.co/DvWq8aXXQX

  • Mashup Score: 7

    Drug resistance results in poor outcomes for most patients with metastatic cancer. Adaptive Therapy (AT) proposes to address this by exploiting presumed fitness costs incurred by drug-resistant cells when drug is absent, and prescribing dose reductions to allow fitter, sensitive cells to re-grow and re-sensitise the tumour. However, empirical evidence for treatment-induced fitness change is lacking. We show that fitness costs in chemotherapy-resistant ovarian cancer cause selective decline and apoptosis of resistant populations in low-resource conditions. Moreover, carboplatin AT caused fluctuations in sensitive/resistant tumour population size in vitro and significantly extended survival of tumour-bearing mice. In sequential blood-derived cell-free DNA and tumour samples obtained longitudinally from ovarian cancer patients during treatment, we inferred resistant cancer cell population size through therapy and observed it correlated strongly with disease burden. These data have enabled

    Tweet Tweets with this article
    • RT @dr_lockley: Preprint! https://t.co/Wl3rqwmgrC We address one of the biggest challenges in cancer care today, namely drug resistance